Triple-negative breast cancer immunotherapeutic efficacy is greatly affected by oxidative imbalance within the lymph nodes, driving dendritic cell dysfunction. Here, this group presents a chimeric exosome-derived immunomodulator involving ROS scavenger mesoporous silica and lipid modulator toyocamycin coated with dendritic cell-derived exosomes to restore the lymph node immuno-microenvironment in triple-negative breast cancer.
- Mengchi Sun
- Yuxia Wu
- Qiuhua Luo
